Issued 2026-09-16 at $59.11 · now $59.11 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, DRUG has typically landed between $39.36 and $84.08 — a range of −33.4% to +42.2% from the issuance price $59.11.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,352 overlapping 1 month windows · 2021-03-22 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($59.11) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where DRUG has typically landed a month from the 2026-09-16 close of $59.11 — the range is history, not a prediction.
- now $59.11 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $56.31 (-4.7%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $47.43–$65.19
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $39.36–$84.08
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-08-29 | −56.9% | −58.3% | +0.0% |
| 2022-08-25 | −55.4% | −57.4% | +2.1% |
| 2023-08-08 | −53.0% | −53.0% | +0.0% |
| 3 best | |||
| 2024-10-03 | +5016.5% | −3.7% | +5016.5% |
| 2024-10-02 | +4728.6% | −6.3% | +4728.6% |
| 2024-10-01 | +4499.1% | −4.5% | +4499.1% |
1,352 overlapping windows · 2021-03-22 – 2026-09-16 · not cherry-picked
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Cormorant Asset Management, LP | other | Sale | 109,331 @ $89.50 | $9.8M | −10.3% of holding | −5.5% | not yet — horizon still open | 950,000 | Form 4 · filed 2 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.